SciELO - Scientific Electronic Library Online

vol.38 issue1Hyperuricemia is associated with progression of chronic kidney disease in patients with reduced functioning kidney massHyponatremia in refractory congestive heart failure patients treated with icodextrin-based peritoneal dialysis: A case series author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995


ESTEVE, Vicent et al. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome. Nefrología (Madr.) [online]. 2018, vol.38, n.1, pp.79-86. ISSN 1989-2284.


Restless legs syndrome (RLS) is a neurological disorder characterised by bothersome symptoms associated with impaired quality of life and sleep hygiene. Rotigotine is a novel therapeutic alternative, although few studies have been published in patients on haemodialysis (HD) with RLS treated with rotigotine.


1.- To establish the prevalence of RLS in our HD unit. 2.- To evaluate the efficacy and safety profile of rotigotine and its effect on symptoms, quality of life and sleep hygiene in our HD population with RLS.

Material and methods:

A single-centre, 12-week prospective study. Two stages (6 weeks): stage 1 (no treatment) and stage 2 (rotigotine). We analysed: 1.- Demographic data, biochemistry data, HD suitability parameters and RLS medical treatment data. 2.- Lower extremity symptoms questionnaire (QS). 3.- RLS severity symptoms scale (SRLSS). 4.- RLS Quality of life: John Hopkins RLS-QoL (JH-QoL). 5.- Sleep hygiene: SCOPA Scale.


We included 66 HD patients, 14 with RLS; 44.4% male, 70.2 ± 9.9 years and 111.1 ± 160.8 months on HD. And 22.9% RLS. Exclusively in stage 2, a significant improvement for QS (10 ± 2.4 vs. 5.7 ± 1.0), SRLSS (21 ± 4 vs. 5.7 ± 4.6), JH-QoL (22.1 ± 4.4 vs. 4.3 ± 4.0) and SCOPA (16 ± 5.3 vs. 6.7 ± 1.9) were observed. A 77.7 and 11.1%, showed partial (> 20%) and complete (> 80%) remission, respectively, while 55.5% achieved «zero» symptoms. Only one patient had gastrointestinal intolerance and none experienced augmentation effect. No changes in biochemical data, suitability for dialysis or medical treatment were found. The inter-group analysis showed a significant improvement in relation to QS, SRLSS, JH-QoL and SCOPA in stage 2.


RLS showed a considerable prevalence in our HD unit. Rotigotine improved clinical symptoms, quality of life and sleep hygiene in RLS patients on HD and was found to be a safe drug with minimal side effects and total therapeutic compliance. Nevertheless, future studies should be performed to confirm the benefits of rotigotine in RLS patients on haemodialysis.

Keywords : Restless legs síndrome; Haemodialysis; Rotigotine.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )